UCB SA Total Liabilities
UCB SA total liabilities. Based on the latest financial reports, UCB SA (UCB) has total liabilities worth €8.98 Billion EUR (≈ $10.50 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See UCB SA (UCB) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of UCB SA (2000–2025)
Total liabilities of UCB SA from 2000 to 2025. This chart illustrates how UCB SA's total liabilities have evolved over time, based on quarterly financial data. Check UCB SA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
UCB SA Competitors by Total Liabilities
The table below lists competitors of UCB SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ERSTE GP BNK AG ADR 1/2
F:EBOR
|
Germany | €409.72 Billion |
|
Chunghwa Telecom Co
TW:2412
|
Taiwan | NT$135.08 Billion |
|
RIO Tinto Ltd
AU:RIO
|
Australia | AU$61.12 Billion |
|
3I GROUP PLC ADR 1/2
F:IGQ
|
Germany | €1.45 Billion |
|
FORTESCUE MET.GR.SP.ADR 2
F:FVJA
|
Germany | €11.33 Billion |
|
Roper Technologies Inc
NASDAQ:ROP
|
USA | $16.47 Billion |
|
Powszechna Kasa Oszczednosci Bank Polski SA
WAR:PKO
|
Poland | zł533.98 Billion |
|
Semiconductor Manufacturing Intl Co
SHG:688981
|
China | CN¥17.25 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down UCB SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is UCB SA's balance sheet.
Liquidity & Leverage Metrics
UCB SA Total Liabilities Ratios Explained
UCB SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how UCB SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for UCB SA (2000–2025)
The table below shows the annual total liabilities of UCB SA from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.29 Billion ≈ $8.52 Billion |
-0.37% |
| 2024-12-31 | €7.32 Billion ≈ $8.56 Billion |
+11.49% |
| 2023-12-31 | €6.56 Billion ≈ $7.67 Billion |
-3.53% |
| 2022-12-31 | €6.80 Billion ≈ $7.95 Billion |
+16.83% |
| 2021-12-31 | €5.82 Billion ≈ $6.81 Billion |
-3.69% |
| 2020-12-31 | €6.05 Billion ≈ $7.07 Billion |
+48.50% |
| 2019-12-31 | €4.07 Billion ≈ $4.76 Billion |
-4.39% |
| 2018-12-31 | €4.26 Billion ≈ $4.98 Billion |
+1.87% |
| 2017-12-31 | €4.18 Billion ≈ $4.89 Billion |
-11.70% |
| 2016-12-31 | €4.74 Billion ≈ $5.54 Billion |
-12.48% |
| 2015-12-31 | €5.41 Billion ≈ $6.32 Billion |
+2.89% |
| 2014-12-31 | €5.26 Billion ≈ $6.15 Billion |
-3.29% |
| 2013-12-31 | €5.44 Billion ≈ $6.36 Billion |
+14.05% |
| 2012-12-31 | €4.77 Billion ≈ $5.57 Billion |
+9.46% |
| 2011-12-31 | €4.36 Billion ≈ $5.09 Billion |
-0.50% |
| 2010-12-31 | €4.38 Billion ≈ $5.12 Billion |
-6.93% |
| 2009-12-31 | €4.70 Billion ≈ $5.50 Billion |
-14.60% |
| 2008-12-31 | €5.51 Billion ≈ $6.44 Billion |
+4.08% |
| 2007-12-31 | €5.29 Billion ≈ $6.19 Billion |
-7.50% |
| 2006-12-31 | €5.72 Billion ≈ $6.69 Billion |
+147.83% |
| 2005-12-31 | €2.31 Billion ≈ $2.70 Billion |
-32.29% |
| 2004-12-31 | €3.41 Billion ≈ $3.98 Billion |
+160.76% |
| 2003-12-31 | €1.31 Billion ≈ $1.53 Billion |
+23.83% |
| 2002-12-31 | €1.06 Billion ≈ $1.23 Billion |
-10.05% |
| 2001-12-31 | €1.17 Billion ≈ $1.37 Billion |
+6.95% |
| 2000-12-31 | €1.10 Billion ≈ $1.28 Billion |
-- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more